Processa Pharmaceuticals Reports Promising Phase 2 Results for Breast Cancer Therapy
NGC-Cap shows enhanced cancer-killing exposure with comparable safety ahead of 2026 interim analysis Processa Pharmaceuticals (PCSA) provided a positive clinical ...









